Sab biotherapeutics presents virtual 2023 r&d day portfolio update: breakthrough immunotherapy innovations

Sioux falls, s.d., may 19, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (higg), also known as fully-human polyclonal antibodies, without the need for human donors, announced today that it will be hosting its virtual 2023 annual r&d day on wednesday, june 14, 2023, at 1:30 p.m. ct.
SABS Ratings Summary
SABS Quant Ranking